Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,438Revenue $M4,464Net Margin (%)7.4Altman Z-Score4.7
Enterprise Value $M16,553EPS $2.0Operating Margin %10.9Piotroski F-Score7
P/E(ttm)45.2Beneish M-Score-2.6Pre-tax Margin (%)9.4Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-5.1Quick Ratio1.4Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-10.3Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow160y-y EBITDA Growth Rate %64.3ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)10.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M173ROIC % (ttm)9.0Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPJohn Rogers 2015-03-31 Sold Out -1.6%$60.63 - $88
($78.39)
$ 89.3514%Sold Out0
HSPVanguard Health Care Fund 2015-03-31 Sold Out -1.1%$60.63 - $88
($78.39)
$ 89.3514%Sold Out0
HSPMario Gabelli 2015-03-31 Add0.22%$60.63 - $88
($78.39)
$ 89.3514%Add 136.77%834,303
HSPJoel Greenblatt 2014-12-31 Sold Out -0.16%$48.12 - $62.84
($56.62)
$ 89.3558%Sold Out0
HSPJohn Rogers 2014-12-31 Reduce-0.08%$48.12 - $62.84
($56.54)
$ 89.3558%Reduce 5.02%2,311,309
HSPVanguard Health Care Fund 2014-12-31 Reduce-0.05%$48.12 - $62.84
($56.54)
$ 89.3558%Reduce 4.87%7,966,970
HSPMario Gabelli 2014-12-31 Add0.03%$48.12 - $62.84
($56.51)
$ 89.3558%Add 38.25%352,370
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 89.3568%Reduce 22.28%2,433,369
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 89.3568%New holding313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 89.3568%Add 24.71%254,870
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 89.3589%Reduce 24.15%3,130,809
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 89.3589%Add 32.91%204,370
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 89.35109%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 89.35109%Reduce 11.62%4,127,850
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 89.35109%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 89.35109%Add 30.68%153,770
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 89.35122%Add 5.28%4,670,630
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 89.35124%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 89.35124%Reduce 7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 89.35164%Add 12.97%4,811,105
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HSP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOWLES BARBARA LDirector 2015-05-21Sell4,000$88.111.41view
Stober Matthew RSVP, Operations 2015-03-02Sell21,833$87.492.13view
Stober Matthew RSVP, Operations 2015-02-27Sell25,338$87.472.15view
Werner Thomas ESVP, Finance & CFO 2015-02-17Sell1,566$87.352.29view
Werner Thomas ESVP, Finance & CFO 2015-01-15Sell10,000$61.5645.14view
Stober Matthew RSVP, Operations 2015-01-12Sell2,000$61.844.58view
Werner Thomas ESVP, Finance & CFO 2014-12-15Sell10,000$60.8646.81view
Hoffman Richard JCVP, Controller & CAO 2014-12-02Sell21,850$60.3248.13view
SOKOLOV JACQUE JDirector 2014-11-28Sell7,547$60.3248.13view
Yoskowitz Marc JSVP, Strategy & Corporate Dev 2014-11-25Sell11,523$59.9349.09view

Quarterly/Annual Reports about HSP:

News about HSP:

Articles On GuruFocus.com
Skyworks Solutions Tops Highest-Performing S&P 500 Stocks Jun 05 2015 
John Rogers' Ariel Fund Q1 2015 Commentary Apr 16 2015 
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 

More From Other Websites
What's in Store for Hospira (HSP) this Earnings Season? - Analyst Blog Jul 27 2015
Street Talk: AVG under the radar Jul 23 2015
Hospira (HSP) Launches Generic Angiomax in the U.S. - Analyst Blog Jul 17 2015
Hospira Announces U.S. Launch of Generic Bivalirudin for Injection Jul 16 2015
Hospira Announces U.S. Launch of Generic Bivalirudin for Injection Jul 16 2015
Hospira to Announce Second-Quarter 2015 Results on July 29, 2015 Jul 15 2015
Hospira to Announce Second-Quarter 2015 Results on July 29, 2015 Jul 15 2015
Appeals Court Makes Medicines Company Angiomax Loss Even Worse Jul 06 2015
5 Best-Performing S&P 500 Stocks Of 2015 Jul 06 2015
Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount Jul 03 2015
10 Best S&P 500 Health Care Stocks Jul 01 2015
Here Are the 10 Best S&P 500 Stocks This Year Jun 30 2015
Apple, Target and eight other companies with the biggest jump in earnings estimates Jun 25 2015
HOSPIRA INC Files SEC form 8-K, Other Events Jun 24 2015
New results from first real-world study show comparable effectiveness and safety of Hospira's... Jun 10 2015
New results from first real-world study show comparable effectiveness and safety of Hospira's... Jun 10 2015
Skyworks Solutions Tops Highest-Performing S&P 500 Stocks Jun 05 2015
ANVISA Approves First Infliximab Biosimilar in Brazil Jun 02 2015
ANVISA Approves First Infliximab Biosimilar in Brazil Jun 02 2015
10 companies with the biggest earnings surprises May 22 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK